Ajay Nehra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ajay Nehra has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Allen D. Seftel
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey
2 shared publicationsAndre T. Guay
Center for Sexual Function/Endocrinology, Lahey Clinic Medical Center, Peabody, Massachusetts
2 shared publicationsArthur L. Burnett
The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
2 shared publicationsCharalambos Vlachopoulos
Athens Medical School, Athens, Greece
2 shared publicationsCulley C. Carson
University of North Carolina, Chapel Hill, North Carolina
2 shared publicationsFrederick C.W. Wu
Manchester Royal Infirmary, Manchester, United Kingdom
2 shared publications
Latest Publications
- 10 October 2014
- Published by Springer Nature
- p. 213-229
Basic Principles of the Princeton Recommendations
- 10 October 2014
- Published by Springer Nature
- p. 213-229
Basic Principles of the Princeton Recommendations
- Open Access
- 1 January 2014
- Published by Medknow in Indian Journal of Urology
- Vol. 30 (4) , 434-42
Erectile dysfunction in robotic radical prostatectomy: Outcomes and management
Robot-assisted laparoscopic prostatectomy (RALP) has emerged as the most common treatment for localized prostate cancer. With improved surgical precision, RALP has produced hope of improved potency rates, especially with the advent of nerve-sparing and other modified techniques. However, erectile dysfunction (ED) remains a significant problem for many men regardless of surgical technique. To identify the functional outcomes of robotic versus open and laparoscopic techniques, new robotic surgical techniques and current treatment options of ED following RALP. A Medline search was performed in March 2014 to identify studies comparing RALP with open retropubic radical prostatectomy (RRP) and laparoscopic radical prostatectomy, modified RALP techniques and treatment options and management for ED following radical prostatectomy. RALP demonstrates adequate potency rates without compromising oncologic benefit, with observed benefit for potency rates compared with RRP. Additionally, specific surgical technical modifications appear to provide benefit over traditional RALP. Phosphodiesterase-5 inhibitors (PDE5I) demonstrate benefit for ED treatment compared with placebo. However, long-term benefit is often lost after use. Other therapies have been less extensively studied. Additionally, correct patient identification is important for greatest clinical benefit. RALP appears to provide beneficial potency rates compared with RRP; however, these effects are most pronounced at high-volume centers with experienced surgeons. No optimal rehabilitation program with PDE5Is has been identified based on current data. Additionally, vacuum erection devices, intracavernosal injections and other techniques have not been well validated for post RALP ED treatment.
- 1 January 2014
- Published by Medknow in Indian Journal of Urology
- Vol. 30 (4) , 434-42
Open AccessErectile dysfunction in robotic radical prostatectomy: Outcomes and management
Robot-assisted laparoscopic prostatectomy (RALP) has emerged as the most common treatment for localized prostate cancer. With improved surgical precision, RALP has produced hope of improved potency rates, especially with the advent of nerve-sparing and other modified techniques. However, erectile dysfunction (ED) remains a significant problem for many men regardless of surgical technique. To identify the functional outcomes of robotic versus open and laparoscopic techniques, new robotic surgical techniques and current treatment options of ED following RALP. A Medline search was performed in March 2014 to identify studies comparing RALP with open retropubic radical prostatectomy (RRP) and laparoscopic radical prostatectomy, modified RALP techniques and treatment options and management for ED following radical prostatectomy. RALP demonstrates adequate potency rates without compromising oncologic benefit, with observed benefit for potency rates compared with RRP. Additionally, specific surgical technical modifications appear to provide benefit over traditional RALP. Phosphodiesterase-5 inhibitors (PDE5I) demonstrate benefit for ED treatment compared with placebo. However, long-term benefit is often lost after use. Other therapies have been less extensively studied. Additionally, correct patient identification is important for greatest clinical benefit. RALP appears to provide beneficial potency rates compared with RRP; however, these effects are most pronounced at high-volume centers with experienced surgeons. No optimal rehabilitation program with PDE5Is has been identified based on current data. Additionally, vacuum erection devices, intracavernosal injections and other techniques have not been well validated for post RALP ED treatment.
- 1 December 2013
- Published by IMR Press in Journal of Men's Health
- Vol. 10 (4) , 119-120
Men's Health and Diabetes: A Rude Awakening
- 1 December 2013
- Published by IMR Press in Journal of Men's Health
- Vol. 10 (4) , 119-120
Men's Health and Diabetes: A Rude Awakening
- 1 June 2013
- Vol. 65 (2) , 109-15
Review of erectile dysfunction and cardiovascular risk.
Cardiovascular disease (CVD) risk assessment in men with erectile dysfunction (ED) is a critical component of evaluation of patients in the outpatient setting. A multidisciplinary approach is preferred, and multiple validated instruments have described to help gauge CVD risk. We have reviewed the relationships of ED and cardiovascular health, risk factors, pathogenesis, lifestyle modifications, and medical optimization. Moreover, we also took into consideration biomarkers for cardiovascular health and their relationship with ED and sexual dysfunction. We advocate using ED as risk for future CVD events, and review the current literature for the management of ED and CVD.
- 1 June 2013
- Vol. 65 (2) , 109-15
Review of erectile dysfunction and cardiovascular risk.
Cardiovascular disease (CVD) risk assessment in men with erectile dysfunction (ED) is a critical component of evaluation of patients in the outpatient setting. A multidisciplinary approach is preferred, and multiple validated instruments have described to help gauge CVD risk. We have reviewed the relationships of ED and cardiovascular health, risk factors, pathogenesis, lifestyle modifications, and medical optimization. Moreover, we also took into consideration biomarkers for cardiovascular health and their relationship with ED and sexual dysfunction. We advocate using ED as risk for future CVD events, and review the current literature for the management of ED and CVD.
- 1 June 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (6) , 2031-2038
Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk
We established erectile dysfunction as an often neglected but valuable marker of cardiovascular risk, particularly in younger men and men with diabetes. We also reviewed evidence that lifestyle change, combined with informed prescribing of pharmacotherapies used to mitigate cardiovascular risk, can improve overall vascular health and sexual functioning in men with erectile dysfunction. We performed a PubMed® search for articles and guidelines pertinent to relationships between erectile dysfunction and cardiovascular disease, cardiovascular and all cause mortality, and pharmacotherapies for dyslipidemia and hypertension. The clinical guidance presented incorporates the current literature and the expertise of the multispecialty investigator group. Numerous cardiovascular risk assessment tools exist but risk stratification remains challenging, particularly in patients at low or intermediate short-term risk. Erectile dysfunction has a predictive value for cardiovascular events that is comparable to or better than that of traditional risk factors. Interventional studies support lifestyle changes as a means of improving overall vascular health as well as sexual functioning. Statins, diuretics, β-blockers and renin-angiotensin system modifiers may positively or negatively affect erectile function. Furthermore, the phosphodiesterase type 5 inhibitors used to treat erectile dysfunction may have systemic vascular benefits. Erectile dysfunction treatment should be considered secondary to decreasing cardiovascular risk. However, informed prescribing may prevent worsening sexual function in men receiving pharmacotherapy for dyslipidemia and hypertension. As the first point of medical contact for men with erectile dysfunction symptoms, the primary care physician or urologist has a unique opportunity to identify those who require early intervention to prevent cardiovascular disease.
- 1 June 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (6) , 2031-2038
Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk
We established erectile dysfunction as an often neglected but valuable marker of cardiovascular risk, particularly in younger men and men with diabetes. We also reviewed evidence that lifestyle change, combined with informed prescribing of pharmacotherapies used to mitigate cardiovascular risk, can improve overall vascular health and sexual functioning in men with erectile dysfunction. We performed a PubMed® search for articles and guidelines pertinent to relationships between erectile dysfunction and cardiovascular disease, cardiovascular and all cause mortality, and pharmacotherapies for dyslipidemia and hypertension. The clinical guidance presented incorporates the current literature and the expertise of the multispecialty investigator group. Numerous cardiovascular risk assessment tools exist but risk stratification remains challenging, particularly in patients at low or intermediate short-term risk. Erectile dysfunction has a predictive value for cardiovascular events that is comparable to or better than that of traditional risk factors. Interventional studies support lifestyle changes as a means of improving overall vascular health as well as sexual functioning. Statins, diuretics, β-blockers and renin-angiotensin system modifiers may positively or negatively affect erectile function. Furthermore, the phosphodiesterase type 5 inhibitors used to treat erectile dysfunction may have systemic vascular benefits. Erectile dysfunction treatment should be considered secondary to decreasing cardiovascular risk. However, informed prescribing may prevent worsening sexual function in men receiving pharmacotherapy for dyslipidemia and hypertension. As the first point of medical contact for men with erectile dysfunction symptoms, the primary care physician or urologist has a unique opportunity to identify those who require early intervention to prevent cardiovascular disease.
- Top Cited Papers
- 1 August 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (8) , 766-778
The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
- 1 August 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (8) , 766-778
Top Cited PapersThe Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
- 1 March 2011
- Published by MRE Press in Journal of Men's Health
- Vol. 8 (1) , 2
Editor's Comments